Prevalence and Distribution of Naturally Occurring Antiviral Resistance-Associated Mutations in Treatment-Naïve Chronic Hepatitis B: A Systematic Review and Meta-Analysis
Background: Chronic hepatitis B virus (HBV) infection remains a major global public-health problem and an important cause of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although nucleos(t)ide analogue therapy has substantially improved management, antiviral resistance-associated mutations may occasionally be detected before treatment exposure. Objective: To systematically determine the prevalence and distribution of established primary antiviral resistance-associated mutations among treatment-naïve patients with chronic HBV infection and to estimate the pooled prevalence of patients carrying at least one established primary resistance mutation. Methods: A systematic review and meta-analysis were conducted using a patient-level endpoint defined as the presence of at least one established primary antiviral resistance-associated mutation in a unique treatment-naïve patient. Secondary or compensatory mutations were not counted as primary resistance when occurring alone. Studies using highly sensitive assays, including mutation-specific PCR and next-generation sequencing, were considered separately where appropriate. The review was structured according to PRISMA 2020. Results: The current primary quantitative dataset comprised 42 cohorts involving 9,811 evaluable treatment-naïve participants, of whom 417 carried at least one qualifying primary resistance-associated mutation, giving a crude prevalence of 4.25%. The current random-effects synthesis estimated an overall pooled prevalence of 1.80% (95% CI, 1.04–3.09%). Between-study heterogeneity was very high (I²=93.3%; τ²=2.541; Q=616.02). The approximate 95% prediction interval was 0.08–30.41%. Conclusion: Naturally occurring primary antiviral resistance-associated mutations are detectable in a minority of treatment-naïve patients with chronic HBV infection, but reported prevalence varies substantially according to population, geography, genotype, study design, and assay sensitivity. The pooled estimate should therefore not be interpreted as a universal prevalence applicable to every clinical setting.
Authors
- Isah Abubakar Aliyu (ORCID: https://orcid.org/0000-0002-1484-2837)
- Elijah Ndakotsu Yisa
- Baba Rasheedat Toyosi
- Abdullahi Mohammed
- Yakubu Firdausi
- Usman Abdullahi Muhammad
- Abubakar Halima Sadiya
Institutions
- Al-Hikmah University (NG)
- Newgate University Minna (NG)
- Bayero University Kano (NG)
Publication Details
- Journal
- International Journal of Current Science Research and Review
- Published
- 2026-11-12
- DOI
- https://doi.org/10.47191/ijcsrr/v9-i11-19
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00